biotech · Alzheimer Disease · ABOS
Acumen Pharmaceuticals
Acumen Pharmaceuticals is a biotech organization headquartered in Boston, USA. It trades on NYSE under ticker ABOS. Primary therapeutic focus areas include Alzheimer Disease. NovaPharmaNews links 4 clinical program(s), 0
Boston, USA HQ
66 Employees
Public company Type
ABOS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Employees
- 66
- Programs
- 4
- Drugs
- 9
- Patents
- 6
ACU193-201
Phase 2 · small molecule · Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
ACU193-201 for Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease) is a Phase 2 program (small_molecule) at Acumen Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code ACU193-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acumen Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)
- Status
- active
- Trials
- 1